Submitted:
07 May 2025
Posted:
08 May 2025
You are already at the latest version
Abstract
Keywords:
1. Article Key Messages
2. Introduction
3. Materials and Methods
3.1. Study Design
3.2. Questionnaire Data
3.3. Other Data
3.4. Statistical Analysis
4. Results
5. Discussion
6. Conclusions
Supplementary Materials
Author Contributions
Author Contributions
Ethics Approval and Consent to Participate
Patient Consent Statement
Consent for Publication from Other Sources
Availability of Data and Material
Competing Interests
Funding
Authors’ Contributions
Acknowledgments
List of Abbreviations
References
- Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017, 390, 2769–2778. [Google Scholar] [CrossRef]
- Conrad MA, RJ. Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am. 2017;64:577-91.
- Uhlig, H.H.; Schwerd, T.; Koletzko, S.; Shah, N.; Kammermeier, J.; Elkadri, A.; Ouahed, J.; Wilson, D.C.; Travis, S.P.; Turner, D.; et al. The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel Disease. Gastroenterology 2014, 147, 990–1007.e3. [Google Scholar] [CrossRef]
- Afzali, A.; Wahbeh, G. Transition of pediatric to adult care in inflammatory bowel disease: Is it as easy as 1, 2, 3? World J. Gastroenterol. 2017, 23, 3624–3631. [Google Scholar] [CrossRef] [PubMed]
- Dür, M.; Sadloňová, M.; Haider, S.; Binder, A.; Stoffer, M.; Coenen, M.; Smolen, J.; Dejaco, C.; Kautzky-Willer, A.; Fialka-Moser, V.; et al. Health determining concepts important to people with Crohn's disease and their coverage by patient-reported outcomes of health and wellbeing. J. Crohn’s Colitis 2014, 8, 45–55. [Google Scholar] [CrossRef] [PubMed]
- Chouliaras, G.; Margoni, D.; Dimakou, K.; Fessatou, S.; Panayiotou, I.; Roma-Giannikou, E. Disease impact on the quality of life of children with inflammatory bowel disease. World J. Gastroenterol. 2017, 23, 1067–1075. [Google Scholar] [CrossRef] [PubMed]
- Reed, B.; Rea, K.E.; Claar, R.L.; van Tilburg, M.A.L.; Levy, R.L. Passive Coping Associations With Self-Esteem and Health-Related Quality of Life in Youth With Inflammatory Bowel Disease. Front. Psychol. 2021, 12. [Google Scholar] [CrossRef] [PubMed]
- Plevinsky, J.M.; Greenley, R.N.; Fishman, L.N. Self-management in patients with inflammatory bowel disease: strategies, outcomes, and integration into clinical care. Clin. Exp. Gastroenterol. 2016, ume 9, 259–267. [Google Scholar] [CrossRef]
- Herzer, M.; A Denson, L.; Baldassano, R.N.; A Hommel, K. Patient and Parent Psychosocial Factors Associated With Health-related Quality of Life in Pediatric Inflammatory Bowel Disease. J. Pediatr. Gastroenterol. Nutr. 2011, 52, 295–299. [Google Scholar] [CrossRef] [PubMed]
- Achleitner, U.; Coenen, M.; Colombel, J.-F.; Peyrin-Biroulet, L.; Sahakyan, N.; Cieza, A. Identification of areas of functioning and disability addressed in inflammatory bowel disease-specific patient reported outcome measures. J. Crohn’s Colitis 2012, 6, 507–517. [Google Scholar] [CrossRef] [PubMed]
- van Rheenen, P.F.; Aloi, M.; Biron, I.A.; Carlsen, K.; Cooney, R.; Cucchiara, S.; Cullen, G.; Escher, J.C.; Kierkus, J.; O Lindsay, J.; et al. European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease. J. Crohn’s Colitis 2017, 11, 1032–1038. [Google Scholar] [CrossRef] [PubMed]
- Gray WN, Maddux MH. Current Transition Practices in Pediatric IBD: Findings from a National Survey of Pediatric Providers. Inflamm Bowel Dis. 2016;22(2):372-9.
- Ostromohov, G.; Fibelman, M.; Hirsch, A.; Ron, Y.; Cohen, N.A.; Kariv, R.; Deutsch, L.; Kornblum, J.; Anbar, R.; Maharshak, N.; et al. Assessment of patients' understanding of inflammatory bowel diseases: Development and validation of a questionnaire. United Eur. Gastroenterol. J. 2021, 10, 104–114. [Google Scholar] [CrossRef] [PubMed]
- Gumidyala AP, Plevinsky JM, Poulopoulos N, Kahn SA, Walkiewicz D, Greenley RN. What Teens Do Not Know Can Hurt Them: An Assessment of Disease Knowledge in Adolescents and Young Adults with IBD. Inflamm Bowel Dis. 2017;23(1):89-96.
- Krauthammer, A.; Harel, T.; Zevit, N.; Shouval, D.S.; Shamir, R.; Weiss, B. Knowledge of disease and self-management of adolescents with inflammatory bowel diseases. Acta Paediatr. 2020, 109, 2119–2124. [Google Scholar] [CrossRef] [PubMed]
- Gibson, CH. A concept analysis of empowerment. J Adv Nurs. 1991;16(3):354-61.
- Turner, D.; Ricciuto, A.; Lewis, A.; D’amico, F.; Dhaliwal, J.; Griffiths, A.M.; Bettenworth, D.; Sandborn, W.J.; Sands, B.E.; Reinisch, W.; et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021, 160, 1570–1583. [Google Scholar] [CrossRef] [PubMed]
- Sullivan, M.D. The new subjective medicine: taking the patient's point of view on health care and health. Soc. Sci. Med. 2003, 56, 1595–1604. [Google Scholar] [CrossRef] [PubMed]
- Azevedo, S.; Oliveira, M.M.; Nogueira, P.; Lopes, A.I. Clinical usefulness of patient-reported-outcome-measurement information system in Pediatric Crohn’s Disease: a cross-sectional study. Heal. Qual. Life Outcomes 2024, 22, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Union OJotE. International Standard Classification of Education (ISCED): Commission Regulation (EU) 2013 [.
- Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17(6):1314-21.
- Hyams, J.; Markowitz, J.; Otley, A.; Rosh, J.; Mack, D.; Bousvaros, A.; Kugathasan, S.; Pfefferkorn, M.; Tolia, V.; Evans, J.; et al. Evaluation of the Pediatric Crohn Disease Activity Index: A Prospective Multicenter Experience. J. Pediatr. Gastroenterol. Nutr. 2005, 41, 416–421. [Google Scholar] [CrossRef] [PubMed]
- Otley A, Smith C, Nicholas D, Munk M, Avolio J, Sherman PM, et al. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002;35(4):557-63.
- Carroll, M.W.; Kuenzig, M.E.; Mack, D.R.; Otley, A.R.; Griffiths, A.M.; Kaplan, G.G.; Bernstein, C.N.; Bitton, A.; Murthy, S.K.; Nguyen, G.C.; et al. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD. J. Can. Assoc. Gastroenterol. 2018, 2, S49–S67. [Google Scholar] [CrossRef] [PubMed]
- Van Rheenen, P.F.; Aloi, M.; Assa, A.; Bronsky, J.; Escher, J.C.; Fagerberg, U.L.; Gasparetto, M.; Gerasimidis, K.; Griffiths, A.; Henderson, P.; et al. The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update. J. Crohn's Coliti 2021, 15, 171–194. [Google Scholar] [CrossRef] [PubMed]
- Del Hoyo, J.; Millán, M.; Garrido-Marín, A.; Aguas, M. Are we ready for telemonitoring inflammatory bowel disease? A review of advances, enablers, and barriers. World J. Gastroenterol. 2023, 29, 1139–1156. [Google Scholar] [CrossRef] [PubMed]
Knowledge of the disease
|
Description of the illness experience
|
Coping tools/skills and resilience in managing the disease (relapses/changes in treatment regimens, re-evaluation tests) and stressful life events (family, school, personal events)
|
Secondary gains from the disease
|
School, school skills, satisfaction with school, motivation to go to school
|
Social integration (peer acceptance)
|
Social support
|
Extracurricular and social activities
|
Perception of the future
|
Self-efficacy: Ability to perform a task successfully
|
Transition of care
|
| Gender M/F (%) | 2/8 (20/80) |
| Current age, years, mean (SD) | 15.4 (± 2) |
| Level of education (ISCED)a n (%) | ISCED 2 (lower secondary education): 1 (10)љISCED (Upper secondary education) 3-5: 9 (90) |
| Extracurricular activities n (%) | 4 (40) |
| Disease duration, years, mean (SD) | 5.2 (± 3.6) |
| Age at diagnosis, years, mean (SD) | 12.7 (± 3.4) |
| Time to diagnosis, months, mean (SD) | 4.9 (± 3.6) |
| Paris, age at diagnose n (%) | A1a (<10 years) 5 (50) љA1b (>10<17 years) 5 (50) |
| PCDAI b mean (SD) | 38.8 (± 16.9) |
| Paris, location n (%) | L2 (Colonic): 2 (20)љL3 (Ileocolonic): 4 (40)љL3L4a (Ileocolonic+ Upper discase proximal to Ligament of Treitz):4 (40) |
| Paris, phenotype n (%) | B1 (non-stricturing non-penetrating): 9 (90)љB3 (Penetrating): 1 (10)љPerianal disease 2 (20) |
| Paris growth n (%) | G0 (No evidence of growth delay): 6 (60)љG1 (Growth delay): 4 (40) |
| Need of hospitalization n (%)љAt diagnosisљReadmission during follow-up (N=6)љIn the prior 6 months c | љ6 (60)љ3 (50) љ0 |
| Need of surgery n (%) љAt diagnoseљIn the prior 6 months c | љ1 (10)љ0 |
| Current treatment n (%) | Immunomodulator 3 (30)љAnti-TNF alfa d treatment 5 (50)љUstekinumab e 2 (20) |
| Treatment modifications n patients (%)љDuring follow upљIn the prior 6 months c | љ4 (40)љ0 |
| Need of corticosteroids n (%) | 0 |
| Poor compliance to treatment - n (%) | 0 |
| PCDAI b mean (SD) | 3.0 (4.8) |
| Fecal Calprotectinμg/g, mean (SD) | 424.8 (563.4) |
| IMPACT III f mean (SD) | 81.1 (13.1) |
| PROMIS Measure | Mean (SD) |
| Global Health | 47.1 (13.4) |
| Depressive symptoms | 42.5 (12.1) |
| Anxiety | 39.7 (10.4) |
| Pain interference | 43.3 (7.5) |
| Fatigue | 46.8 (14.7) |
| Life Satisfaction | 44.2 (7.4) |
| Meaning and Purpose | 47.0 (9.6) |
| Cognitive function | 46.7 (11.6) |
| Peer Relationships | 46.8 (13.9) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).